BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37686454)

  • 1. HLA Class I Expression Is Associated with DNA Damage and Immune Cell Infiltration into Dysplastic and Neoplastic Lesions in Ulcerative Colitis.
    Okami H; Ozawa N; Sohda M; Yokobori T; Osone K; Erkhem-Ochir B; Dorjkhorloo G; Shiraishi T; Okada T; Sano A; Sakai M; Miyazaki T; Ogawa H; Yao T; Oike T; Sato H; Shirabe K; Shibata A; Saeki H
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.
    Ozawa N; Yokobori T; Osone K; Katayama C; Suga K; Komine C; Shibasaki Y; Shiraishi T; Okada T; Kato R; Ogawa H; Sano A; Sakai M; Sohda M; Ojima H; Miyazaki T; Motegi Y; Ide M; Yao T; Kuwano H; Shirabe K; Saeki H
    Sci Rep; 2021 Jun; 11(1):13077. PubMed ID: 34158547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAdCAM-1 targeting strategy can prevent colitic cancer carcinogenesis and progression via suppression of immune cell infiltration and inflammatory signals.
    Ozawa N; Yokobori T; Osone K; Bilguun EO; Okami H; Shimoda Y; Shiraishi T; Okada T; Sano A; Sakai M; Sohda M; Miyazaki T; Ide M; Ogawa H; Yao T; Oyama T; Shirabe K; Saeki H
    Int J Cancer; 2024 Jan; 154(2):359-371. PubMed ID: 37676657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity.
    Tsuda S; Carreras J; Kikuti YY; Nakae H; Dekiden-Monma M; Imai J; Tsuruya K; Nakamura J; Tsukune Y; Uchida T; Matsushima M; Roncador G; Suzuki T; Nakamura N; Mine T
    Pathol Int; 2019 May; 69(5):260-271. PubMed ID: 30990953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Immune Infiltration Profiles in Colitis-Associated Colorectal Cancer versus Sporadic Colorectal Cancer.
    Schardey J; Lu C; Neumann J; Wirth U; Li Q; Jiang T; Zimmermann P; Andrassy J; Bazhin AV; Werner J; Kühn F
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of Gene Methylation and Polymorphism in Different Courses of Ulcerative Colitis and Their Comparison with Sporadic Colorectal Cancer.
    Liu C; Yuan ZY; Yuan H; Wu KX; Cao B; Ren KY; Cui MJ; Liu JH; Chen HX; Pang YW
    Inflamm Bowel Dis; 2021 Mar; 27(4):522-529. PubMed ID: 32793962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
    Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
    Front Immunol; 2021; 12():679090. PubMed ID: 34054869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of PD-1/PD-L1 imbalance in ulcerative colitis.
    Shi W; Zhang Y; Hao C; Guo X; Yang Q; Du J; Hou Y; Cao G; Li J; Wang H; Fang W
    PeerJ; 2023; 11():e15481. PubMed ID: 37273534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of programmed death ligand 1 in refractory inflammatory bowel disease.
    Nguyen J; Finkelman BS; Escobar D; Xue Y; Wolniak K; Pezhouh M
    Hum Pathol; 2022 Aug; 126():19-27. PubMed ID: 35489437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
    J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STMN1 accumulation is associated with dysplastic and neoplastic lesions in patients with ulcerative colitis.
    Osone K; Yokobori T; Katayama C; Takahashi R; Kato R; Tatsuski H; Takada T; Yajima R; Motegi Y; Ogawa H; Fujii T; Ojima H; Nakamura J; Yao T; Shirabe K; Kuwano H
    Oncol Lett; 2019 Nov; 18(5):4712-4718. PubMed ID: 31611980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
    Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
    Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
    Rocha P; Rodrigo M; Moliner L; Menendez S; Masfarré L; Navarro N; Del Rey-Vergara R; Galindo-Campos M; Taus Á; Giner M; Sanchez I; Rodríguez-Fuster A; Aguiló R; Chalela R; Sánchez-Font A; Belda J; Curull V; Pijuan L; Casadevall D; Clavé S; Bellosillo B; Perera-Bel J; Comerma L; Arriola E
    Lung Cancer; 2023 Jul; 181():107257. PubMed ID: 37263182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Programmed Death-Ligand 1 by Human Colonic CD90
    Beswick EJ; Grim C; Singh A; Aguirre JE; Tafoya M; Qiu S; Rogler G; McKee R; Samedi V; Ma TY; Reyes VE; Powell DW; Pinchuk IV
    Front Immunol; 2018; 9():1125. PubMed ID: 29910803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical Detection of Bacteria in the Resected Valves was Associated with Stromal Immune Checkpoint Protein Expression that may Contribute to Calcific Aortic Stenosis.
    Erkhem-Ochir B; Tatsuishi W; Yokobori T; Gombodorj N; Saeki H; Shirabe K; Abe T
    Semin Thorac Cardiovasc Surg; 2022; 34(4):1170-1177. PubMed ID: 34688900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.